Literature DB >> 19563891

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.

Nicolas Collin1, Xavier de Radiguès.   

Abstract

The first influenza pandemic of the 21st century, due to a new strain of A(H1N1) virus, was declared on 11 June 2009 by the Director-General of the World Health Organization. Fortunately, the international community, including influenza vaccine manufacturers, has been increasing its preparedness for such an event, triggered by the need to stem the spread of the highly pathogenic avian influenza A(H5N1) virus over recent years. Today, the development of a pandemic influenza vaccine in the fastest possible time is a global priority. However, two major issues need to be taken into consideration: how long will it take to produce sufficient pandemic vaccine doses to immunize the global population at risk, including poor populations that have no resources to purchase the vaccine; and how will pandemic vaccine production affect availability of trivalent vaccine for the forthcoming 2009-2010 influenza season. To address these questions, WHO carried out a survey in May 2009 among influenza vaccine manufacturers on their planned seasonal and pandemic production with a view to developing recommendations on the distribution and use of pandemic influenza vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563891     DOI: 10.1016/j.vaccine.2009.06.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  The new influenza A H1N1 virus: balancing on the interface of humans and animals.

Authors:  Frank J U M van der Meer; Karin Orsel; Herman W Barkema
Journal:  Can Vet J       Date:  2010-01       Impact factor: 1.008

2.  Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

Authors:  Sharon K Greene; Martin Kulldorff; Edwin M Lewis; Rong Li; Ruihua Yin; Eric S Weintraub; Bruce H Fireman; Tracy A Lieu; James D Nordin; Jason M Glanz; Roger Baxter; Steven J Jacobsen; Karen R Broder; Grace M Lee
Journal:  Am J Epidemiol       Date:  2009-12-04       Impact factor: 4.897

3.  Perspective: Ill prepared for a pandemic.

Authors:  Klaus Stöhr
Journal:  Nature       Date:  2014-03-06       Impact factor: 49.962

Review 4.  Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly.

Authors:  Monique P Curran; Isabel Leroux-Roels
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

5.  Two-dose seasonal influenza vaccine coverage and timeliness among children aged 6 months through 3 years: An evidence from the 2010-11 to the 2014-15 seasons in Zhejiang province, east China.

Authors:  Yu Hu; Yaping Chen; Bing Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-09-13       Impact factor: 3.452

6.  Economic analysis of pandemic influenza vaccination strategies in Singapore.

Authors:  Vernon J Lee; Mei Yin Tok; Vincent T Chow; Kai Hong Phua; Eng Eong Ooi; Paul A Tambyah; Mark I Chen
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

7.  Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1.

Authors:  David P Fidler
Journal:  PLoS Med       Date:  2010-05-04       Impact factor: 11.069

8.  Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.

Authors:  Claire S Waddington; W T Walker; C Oeser; A Reiner; T John; S Wilkins; M Casey; P E Eccleston; R J Allen; I Okike; S Ladhani; E Sheasby; K Hoschler; N Andrews; P Waight; A C Collinson; P T Heath; A Finn; S N Faust; M D Snape; E Miller; A J Pollard
Journal:  BMJ       Date:  2010-05-27

Review 9.  Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea.

Authors:  J Steinmann; J Buer; T Pietschmann; E Steinmann
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  The novel influenza A (H1N1) virus pandemic: An update.

Authors:  N Petrosillo; S Di Bella; C M Drapeau; E Grilli
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.